Acute Heart Failure
Conditions
Interventions
rhBNP treatment group:NA
Sponsors
FUWAI Hospital, CAMS&PUMC
Eligibility
Sex/Gender
All
Age
18 Years to No maximum
Inclusion criteria
Inclusion criteria: 1. Age >= 18 years, regardless of gender. 2. Diagnosed with acute heart failure according to the National Heart Failure Guidelines 2023. 3. Patients scheduled to receive recombinant human natriuretic peptide treatment. 4. NT-proBNP >= 450 ng/L at screening. 5. Signed informed consent form.
Exclusion criteria
Exclusion criteria: 1. Cardiogenic shock or persistent systolic blood pressure < 90 mmHg. 2. Diagnosed with severe valvular stenosis, hypertrophic cardiomyopathy, constrictive pericarditis, cardiac tamponade, or severe pulmonary disease. 3. Pregnancy or lactation. 4. Known or suspected allergy to the investigational drug or its components. 5. Participation in other clinical studies within the past month. 6. Any other condition deemed unsuitable for inclusion by the investigator.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Rate of dyspnea improvement at 24 hours ;Change from baseline in serum creatinine (SCr), estimated glomerular filtration rate (eGFR), serum potassium, and Cystatin C at 24h, 72h, and 30 days ;Length of hospital stay for the current acute heart failure episode;30-day and 90-day all-cause mortality + heart failure rehospitalization rate;0-day and 90-day cardiovascular mortality + heart failure rehospitalization rate; | — |
Secondary
| Measure | Time frame |
|---|---|
| dyspnea improvement;dyspnea improvement (assessed by the 7-point Likert scale) at other time points besides 24h of treatment (3h, 48h, 72h, 96h, 120h, 6 days, 7 days);Change from baseline in NT-proBNP levels at 24h, 48h, 72h, 96h, 120h, and 30 days after initiation of treatment;Change from baseline in 24-hour urine output during hospitalization; | — |
Countries
China
Contacts
Public ContactJian Zhang and Yuhui Zhang
FUWAI Hospital, CAMS&PUMC
Outcome results
None listed